http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110128511-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0362 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-245 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-21 |
| filingDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110128511-B |
| titleOfInvention | A kind of recombinant protein for weight loss, vaccine and construction method thereof |
| abstract | The invention belongs to the technical field of vaccines, and discloses a recombinant protein for weight loss, a vaccine and a construction method thereof. The vaccine for weight loss is recombinant protein 1; the protein sequence of the recombinant protein 1 is SEQ ID NO: 1; the recombinant protein 1 The DNA sequence of the gene is SEQ ID NO:2. The invention uses recombinant protein immunization with a unique structure, neutralizes the somatostatin secreted by the body, relatively increases the secretion of growth hormone, and effectively reduces the body weight and fat content of nutritionally obese mice; thereby solving the problem of weight loss drugs in the prior art. It requires long-term use, large adverse reactions, and high treatment costs. |
| priorityDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 316.